Tradestie Institutional Equity Comparison Engine
VRAX vs CING โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CING Overall Edge
CING Captures Institutional Edge (2โ1 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cingulate Inc. Common Stock (CING) driven by superior Momentum & Technical, Options & Structure while VRAX counters with relative strength in Growth & Margin. Fundamentally, VRAX trades at N/M Forward P/E with -51515.2% operating margin (+684.9% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VRAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VRAX N/M vs CING N/M Fwd P/E
Growth & Margin Winner
VRAX
Op Margin -51515.2% vs 0.0% ยท YoY +684.9% vs +0.0%
Momentum & Technical Winner
CING
1Y -6.5% vs +35.4% ยท 52W Pos 3% vs 18%
Options & Structure Winner
CING
UNCLASSIFIED (N/A IV) vs BREAKDOWN (16th %ile IV)
VRAX
NASDAQ
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.46
+2.46% 1D
Market Cap
$823,939
1M Return
-67.21%
1Y Return
-6.52%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 25.0
Fund 44.0
Flow 50.0
Mom 55.0
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap
$62.5M
1M Return
+8.37%
1Y Return
+35.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VRAX -6.52%
CING +35.39%
Spread: +41.91 pp (CING Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
VRAX TTM Op. Margin: -51515.2%
CING TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRAX vs CING. Trailing 12-month operating profitability (VRAX -51515.2% vs CING 0.0%) and valuation multiples (VRAX N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VRAX | CING | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $823,939 | $62.5M | Larger Scale | CING |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +684.9% | +0.0% | Higher Growth | VRAX |
| Operating Margin (TTM) Profitability | -51515.2% | 0.0% | Higher Margin | CING |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -78.6% | -198.7% | Higher ROE | VRAX |
| 52-Week Range Position Momentum | 3% ($0โ$13) | 18% ($3โ$12) | Stronger Trend | CING |
| Beta / 30D Volatility Risk Regime | -9.35ฮฒ ยท 161% Vol | 1.07ฮฒ ยท 121% Vol | Lower Realized Risk | CING |
| Unified Institutional Score Composite Signal | 41.7 / 100 (SELL) | 44.8 / 100 (HOLD) | Higher Composite | CING |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VRAX vs CING Buy Guide
VRAX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VRAX nor CING registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.